NOS2 and cancer: Cancer cells usually succumb to dysregulated levels of NO and S-nitrosylation (either hyper-S-nitrosylation or hypo-S-nitrosylation) owing to the altered expression of nitric oxide synthases (NOS) or denitrosylases as well as oncogenic mutations of target proteins.